Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that its lead product, Apocept , has been granted orphan drug designation from the US Food and Drug Administration for the treatment of Myelodysplastic syndromes .
http://www.medilexicon.com/medicalnews.php?newsid=256181
http://www.medilexicon.com/medicalnews.php?newsid=256181
No comments:
Post a Comment